Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · RAPID MICRO BIOSYSTEMS, INC. (RPID)

Rapid Micro Biosystems Q1 revenue rises 11% to $8.0 million; net loss widens

Mixed Impact 3 of 5 earnings Written later

Rapid Micro Biosystems reported first quarter 2026 total revenue of $8.0 million, up 11.1% from a year earlier, with product revenue up 36.0%. The net loss widened to $14.3 million from $11.3 million, and the company reaffirmed its full year 2026 total revenue guidance of $37.0 million to $41.0 million. For shareholders, revenue growth is offset by a larger loss and cash, short-term investments and restricted cash of about $23 million as of March 31, 2026.

Key points

  • Total revenue rose 11.1% to $8.0 million; product revenue rose 36.0% to $5.6 million, while service revenue fell 21.9% to $2.4 million.
  • Net loss was $14.3 million, or $0.31 per share, versus $11.3 million, or $0.26 per share, in the first quarter of 2025.
  • Full year 2026 total revenue guidance of $37.0 million to $41.0 million was reaffirmed, along with a gross margin target of approximately 20%.
  • Cash, short-term investments and restricted cash were about $23 million on March 31, 2026, down from $38.6 million on December 31, 2025.

The filing

CompanyRAPID MICRO BIOSYSTEMS, INC. (RPID)
Form8-K, current report
Filed with the SECMay 13, 2026, 4:33 PM ET
Accession number0001380106-26-000067

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.